Vanda Pharmaceuticals Inc. 8-K

What Happened
Vanda Pharmaceuticals Inc. filed an 8-K (dated Feb 19, 2026) reporting that its Compensation Committee on Feb 18, 2026 approved 2025 cash bonus payments, set 2026 annual base salaries and bonus targets for named executive officers, and granted restricted stock units (RSUs) and performance RSUs (PSUs). The Committee reviewed an external peer- compensation analysis by Willis Towers Watson before approving the awards. Key cash and equity figures include Mihael Polymeropoulos (CEO) receiving a $834,326 2025 bonus, a $994,625 2026 base salary with an 80% target bonus, and grants of 525,000 RSUs and 175,000 PSUs. Other named executives (CFO Kevin Moran; SVPs Gunther Birznieks, Joakim Wijkstrom, Timothy Williams) received 2025 bonuses of $272,129–$281,686, 2026 base salaries of $576,735–$596,990 with 45% target bonuses, and equity grants of 125,000 RSUs and 40,000 PSUs each.

Key Details

• 2025 cash bonuses paid: CEO Mihael H. Polymeropoulos $834,326; CFO Kevin Moran $272,129; Gunther Birznieks $272,129; Joakim Wijkstrom $281,686; Timothy Williams $272,129.
• 2026 pay/targets: CEO salary $994,625 (80% bonus target); CFO & three SVPs salaries $576,735–$596,990 (45% bonus target).
• Equity grants: CEO 525,000 RSUs & 175,000 PSUs; each other named exec 125,000 RSUs & 40,000 PSUs. RSUs vest in four equal annual installments starting March 1, 2027.
• PSUs measure relative Total Stockholder Return (TSR) vs. the Nasdaq Biotechnology Index over 12/31/2025–12/31/2028; payouts range from 0% (<25th percentile) to 150% (≥75th percentile) of target, with earned PSUs vesting March 1, 2029. No dividends accrue on PSUs.

Why It Matters
This filing details material changes to executive compensation and significant equity awards that can affect dilution, executive incentives, and alignment with shareholder returns. The PSU structure ties a meaningful portion of pay to Vanda’s TSR performance versus biotech peers, while large RSU grants create multi-year retention incentives. Investors should note the sizes of the equity grants (especially the CEO’s awards), the performance metric (relative TSR), and the vesting schedule when assessing potential dilution and management incentives.